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Summary
Cytomegalovirus (CMV) usually causes lifelong asymptomatic infection, but
over time can distort immune profiles. Recent reports describe selective
expansion of Vδ2neg γδ T cells in healthy and immunocompromised CMV
carriers. Having shown previously that virus-specific CD8+ and CD4+ T cell
responses are increased significantly in elderly CMV carriers, probably
driven by chronic stimulation, we hypothesized that Vδ2neg γδ T cells may
also be expanded with age. Our results show that Vδ2neg γδ T cells are
increased significantly in CMV-seropositive healthy individuals compared to
CMV-seronegative controls in all age groups. The differences were most sig-
nificant in older age groups (P < 0·0001). Furthermore, while Vδ2neg γδ T-
cells comprise both naive and memory cells in CMV-seronegative donors,
highly differentiated effector memory cells are the dominant phenotype in
CMV carriers, with naive cells reduced significantly in numbers in CMV-
seropositive elderly. Although phenotypically resembling conventional
CMV-specific T cells, Vδ2neg γδ T cells do not correlate with changes in mag-
nitude of CMV-specific CD4+ or CD8+ T cell frequencies within those indi-
viduals, and do not possess ex-vivo immediate effector function as shown by
CMV-specific CD4+ and CD8+ T cells. However, after short-term culture,
Vδ2neg γδ T cells demonstrate effector T cell functions, suggesting additional
requirements for activation. In summary, Vδ2neg γδ T cells are expanded in
many older CMV carriers, demonstrating a further level of lymphocyte
subset skewing by CMV in healthy individuals. As others have reported
shared reactivity of Vδ2neg γδ T cells towards tumour cells, the composition
of γδ T cell subsets may also have implications for risk of developing cancer
in elderly people.
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Introduction
Cytomegalovirus (CMV) establishes a lifelong usually
asymptomatic infection in immunocompetent individuals
[1], which is associated with profound effects on the host
immune repertoire [2]. We and others have shown that
CMV drives massive oligoclonal expansions of both CD4+
and/or CD8+ virus-specific memory T cells in healthy carri-
ers which increase with age [3–6], a process termed as
memory inflation [4]. These T cell responses are frequently
more than 1% of the respective subset in young virus carri-
ers, and often exceed 10% of CD4+/CD8+ T cells in the
elderly [5,6]. CMV-specific T cells are predominantly
CD28low effector memory T cells (Tem) [7], producing high
amounts of proinflammatory cytokines such as interferon
(IFN)-γ and tumour necrosis factor (TNF)-α. Such high
frequencies of Tem cells may be useful for limiting viral rep-
lication, but could also induce greater inflammation that
is damaging at the tissue level [8]. This accumulation
of CD28low Tem cells is also considered a marker of
immunosenescence, the deterioration of immune function
with age [9].
While CD4+ and CD8+ T cell responses have been charac-
terized in great detail [10–13], there is growing evidence
that non-conventional T cells expressing gamma-delta (γδ)
T receptor cells (TCR) are important in protection against
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CMV. Unlike αβ (CD4+/CD8+) T cells, γδ T cells are major
histocompatibility complex (MHC)-unrestricted in their
antigen recognition and normally constitute a minority of
circulating T cells. However, γδ T cells are expanded or acti-
vated in infections and in malignancy [14–18], and also dif-
ferentiate into memory cells much earlier in life than αβ T
cells, indicating a major role in responding against patho-
genic insult from birth [19]. Dechanet-Merville and col-
leagues have shown that γδ T cells are considerably
expanded (reaching 40% of circulating T cells) following
primary CMV infection in CMV-seronegative transplant
recipients of kidneys from CMV-seropositive donors [20–
22]. Early γδ T cell reconstitution correlated with improved
control of CMV replication, and the expansions were com-
posed of either Vδ1pos or Vδ3pos cells, but not Vδ2pos cells
[20]. Similar Vδ2neg γδ T cell expansions have also been
reported very recently in CMV-infected allogeneic stem cell
transplant patients and in CMV-infected fetuses [23,24].
The selective expansion of Vδ2neg γδ T cells (Vδ1pos and
Vδ3pos) in CMV-infected hosts implies that these γδ T cells
are involved in immunity. Expanded Vδ2neg γδ T cell lines
specifically secrete cytokines and demonstrate cytotoxicity
after incubation with CMV-infected target cells in vitro, but
not uninfected targets or target cells infected with other
herpesviruses [25]. It has been shown recently that Vδ2neg γδ
T cells are also expanded in healthy CMV carriers [26] but
it is unclear whether, like CMV-specific CD4+ and CD8+ T
cells, Vδ2neg γδ T cells also expand with age. The persistent
nature of CMV infection is thought to drive CD4+/CD8+ T
cell memory inflation over time. Thus, we aimed to test our
hypothesis that Vδ2neg γδ T cell expansions occur more fre-
quently in CMV carriers of older age.
Materials and methods
Study volunteers
A total of 255 healthy adult volunteers, aged 20–85 years,
and two non-immunocompromised patients diagnosed
with symptomatic primary CMV infection formally con-
sented to donate blood samples for the study. Ethical
approval was obtained from local Adult Research Ethics
Committees (REC reference 2K/175 and 09/H1005/51).
CMV status was determined using plasma samples with a
commercial CMV immunoglobulin (Ig)G enzyme-linked
immunosorbent assay (ELISA) kit (Biocheck Inc., Foster
City, CA, USA). Diamedix herpes simplex virus (HSV) IgG
and varicella zoster virus (VZV) IgG kits (Launch Diagnos-
tics, Longfield, UK) was used for HSV and VZV seropositiv-
ity and viral capsid antigen (VCA) staining had been
performed previously for Epstein–Barr virus (EBV) serop-
ositivity. Absolute lymphocyte counts were determined by
the Blood Sciences Department at the Royal Liverpool Uni-
versity Hospital NHS Trust.
Antibodies and flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated
from donor blood and resuspended in fluorescence acti-
vated cell sorter (FACS) buffer [phosphate-buffered saline
(PBS) containing 0·1% bovine serum albumin (BSA) and
2 mM ethylenediamine tetraacetic acid (EDTA)], and then
incubated with different combinations of monoclonal anti-
bodies (mAb) for 20 min at 4°C at the manufacturer’s rec-
ommended concentrations. The following mAb were used:
TCR-γδ-allophycocyanin (APC), TCR-αβ-phycoerythrin
(PE), Vδ2-PE, lymphocyte function-associated antigen 1
(LFA-1)-fluorescein isothiocyanate (FITC), CD4-APC (all
purchased from BD Biosciences, San Jose, CA, USA),
CD8-PE (Dako, Glostrup, Denmark), Vδ1-FITC (Thermo
Fisher Scientific, Loughborough, UK), Vδ2-peridinin chlo-
rophyll (PerCP), CD45RA-Alexa-Fluor 700, CD45RA-
PerCP-cyanin (Cy)5.5 and CD28-PerCP-Cy5.5 (all from
Cambridge Bioscience, Cambridge, UK), CD27-APC
eFluor780 (eBioscience, San Diego, CA, USA), CD57-FITC
(AbD Serotec, Kidlington, UK) and CCR7-FITC (R&D
Systems, Minneapolis, MN, USA). Intracellular staining was
performed with perforin-FITC, granzyme B-PE, IFN-γ-
PerCP-Cy5.5 and TNF-α-FITC (all from BD Biosciences).
Analysis was performed using a Becton Dickinson
FACSCalibur or LSR II flow cytometer. Data were analysed
later using Win MDI 2.8 software (The Scripps Institute:
http://facs.scripps.edu/software.html) and/or diva software
(BD Biosciences).
Assays of T cell function
CMV-specific CD4+ and CD8+ T cells were detected as
described elsewhere [5,27]. Briefly, PBMC were stimulated
for 6 h at 37°C (5% CO2) with CMV or mock lysates, or
with a cocktail of synthetic peptides (purchased from
Invitrogen, Carlsbad, CA, USA) representing published
immunodominant human leucocyte antigen (HLA) class
I-restricted CMV epitopes from six viral antigens (see [28]).
Brefeldin A was added (10 μg/ml final concentration) after
1 h of incubation. Cells were then stained for surface
markers and afterwards for intracellular cytokines. Appro-
priate isotype controls were used for each test.
γδ T cell functional assays involved enrichment of PBMC
for γδ T cells using a TCR-γδ T cell isolation kit (Miltenyi
Biotec, Bergisch Gladbach, Germany), as per the manufac-
turer’s instructions. In some cases Vδ2 cell depletion was
also carried out. γδ T cell lines were generated by co-culture
of enriched γδ T cells with irradiated phycohaemagglutinin
(PHA)-activated allogeneic PBMC and stimulation with
30 ng/ml anti-CD3 (OKT3; Cambridge Bioscience Ltd) and
100 U/ml of recombinant interleukin 2 (rIL-2) (Peprotech,
London, UK). T cell lines were maintained in medium sup-
plemented with 100 U/ml of rIL-2 for up to 4 weeks.
Unmanipulated or cultured cells were co-incubated with
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uninfected human fetal foreskin fibroblasts (HFFF) or
HFFF infected for 3–4 days with the AD169 strain of CMV
(at multiplicity of infection 1:1). After 6 h at 37°C (with
brefeldin A added at 1 h), PBMC were removed and washed
before staining for surface markers and cytoplasmic IFN-γ
and TNF-α. In parallel experiments, tubes were incubated
with FITC-conjugated anti-CD107a (BD Biosciences) at the
beginning of the incubation, to determine degranulation as
a consequence of stimulation.
T cell lines were also tested for IFN-γ secretion using
supernatants taken from overnight-stimulated (with CMV-
infected or non-infected fibroblasts) cultures by ELISA
(eBioscience) in accordance with the manufacturer’s rec-
ommended protocol. Blocking assays were performed by
preincubating effector cells with anti-TCR-Vδ1, anti-TCR-
Vδ2 or mouse isotype control mAb. For positive controls,
cells were stimulated with 20 ng/ml PMA and 1 μg/ml
ionomycin (both from Sigma, Poole, UK).
Statistical analyses
These were performed with Graphpad Prism software
(GraphPad Software Inc., La Jolla, CA, USA). The Mann–
Whitney U-test was applied with 95% confidence intervals
to test differences in γδ T cell frequencies between different
donor groups. The non-parametric Spearman’s rank corre-
lation coefficient was used to assess correlations between
different T cell subset frequencies. All P-values were two-
tailed, and for multiple comparisons subjected to Holm–
Bonferroni correction.
Results
γδ T cell subsets are skewed by CMV carriage in
older individuals
Our initial investigation of γδ T cells in 255 healthy volun-
teers (125 CMV-seropositives/130 CMV-seronegatives) aged
21–85 years showed considerable variation in frequency of
different γδ T cell subsets in blood. In some individuals
Vδ1pos cells were the major γδ type, while in others Vδ2pos
cell expansions were observed (see representative examples
in Supporting information, Fig. S1). We could not stain
directly for Vδ3pos γδ T cells (due to lack of specific mAb),
but as they were also expanded in a small number of indi-
viduals we measured the total Vδ2neg γδ population to
include for Vδ3pos cells. Overall, Vδ2neg γδ T cells were sig-
nificantly higher (P < 0·0001) in CMV-seropositive donors
than in CMV-seronegative donors (see Fig. 1a). This coin-
cided with reduced Vδ2pos γδ T cells in CMV carriers, but
was not statistically significant (Fig. 1a). However, the total
γδ T cell frequency in CMV-seropositive and CMV-
seronegative donors was very similar (Fig. 1b). To confirm
that this effect was CMV-associated, we tested for other
human herpesviruses, HSV-1/2, EBV and VZV. Statistical
analysis did not show any significant difference in γδ T cell
subsets between seropositive and seronegative donors for
these viruses (data not shown), in agreement with work
published by others [26].
We then examined if Vδ2neg γδ T cells increased with age
(see Fig. 1c). A number of middle- and older-aged donors
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Fig. 1. γδ T cell subsets in healthy donors. Charts summarizing the γδ
T cell staining results from 255 healthy donors are shown for Vδ2pos
and Vδ2neg γδ T cells (a) and total γδ T cells (b). Vδ2neg γδ T cell
frequencies with increasing age in cytomegalovirus
(CMV)-seropositive and CMV-seronegative donors (c). Comparison
of Vδ2pos and Vδ2neg γδ T cells between CMV-seropositive and
CMV-seronegative donors in each of the defined age groups (d).
Values on the y-axis indicate the percentage of total T lymphocytes
represented by each subset. P-values are shown above each plot with
95% confidence intervals applied.
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had Vδ2neg γδ T cell expansions approaching 10% (or more)
of all T cells, with the highest observed frequency at 41% of
all T cells in one healthy elderly donor; findings that are
very similar to that of increased CMV-specific CD4+ and
CD8+ T cells in healthy elderly virus carriers. However, the
increase in Vδ2neg cells with age was not statistically signifi-
cant (P = 0·78). Interestingly, there was a significant reduc-
tion of Vδ2neg cells in the CMV-seronegative group with age
(P < 0·0001). Further analysis within separate age groups
termed hereafter as young, aged 21–40 years (n = 97),
middle-aged, aged 41–60 years (n = 83) and elderly, aged
61–85 years (n = 75), showed that Vδ2neg γδ T cells were sig-
nificantly higher in CMV carriers of all age groups when
compared with age-matched CMV-seronegative donors,
both as frequency of total T cells and as the absolute
number of cells (see Table 1). In contrast, Vδ2pos γδ T cells
were not significantly different between CMV-seropositive
and CMV-seronegative subjects in any age group.
Identification of naive and memory γδ T cell subsets
Total γδ T cells contain both naive (LFA-1low CD45RAhigh)
and memory cells (LFA-1high CD45RAhigh/low) [19]. We thus
determined whether naive and memory γδ T cell subsets
were affected by CMV carriage in different age groups.
Figure 2a,b shows representative examples of Vδ2pos and
Vδ2neg γδ T cells in different donors. While Vδ2pos cells were
overwhelmingly CD45RAlow memory cells in both CMV-
seropositive and seronegative donors, Vδ2neg cells showed a
distinct naive/memory profile which appeared to be linked
to CMV status. In CMV-seropositive donors the Vδ2neg γδ
subset was skewed towards CD45RAhigh revertant memory
cells (denoted TemRA), very much like that observed for
CMV-specific CD8 T cells. Overall, there was an increase in
memory Vδ2neg cells with age in CMV carriers, but this did
not reach statistical significance (Supporting information,
Fig. S2a). However, memory Vδ2neg cells were reduced sig-
nificantly in numbers as CMV-seronegative subjects became
older (Supporting information, Fig. S2b).
Further analysis showed that, independent of CMV
status, there was a significant decrease in absolute numbers
of naive cells in elderly donors (Fig. 2c) when compared
with middle-aged and young donors (both P < 0·0001).
CMV carriage associated with reduced naive Vδ2neg cells in
each group (Fig. 3d), but this only reached statistical signifi-
cance in elderly donors (P = 0·01).
Comparative analysis of Vδ2neg γδ T cells with
virus-specific CD4+ and CD8+ T cells
Although Vδ2neg γδ T cells were higher in older population
groups, there was considerable interindividual variation
within all age groups. We questioned whether this variation
was due to differences in frequencies of CMV-specific CD4+
and CMV-specific CD8+ T cells, both parameters also
varying considerably between individuals in each group.
CD4+ T cell frequency was based on IFN-γ responses against
CMV lysate and CD8+ T cell responses were based on
responses against a peptide cocktail representing six
immunodominant antigens (IE-1, IE-2, pp65, pp50, gB,
pp150), which would cover 90% of responders. This does
not represent the complete CMV-specific T cell response,
which could involve over 100 viral antigens [13]; however,
this would be impractical to measure in a large cohort study
such as ours. The results (Fig. 3) showed that frequencies of
Vδ2neg γδ T cells did not correlate with the CD8+ T cell
response (r 2 = 0·034; P = 0·847) or CD4+ T cell response
(r 2 = 0·102; P = 0·559). Some individuals had large Vδ2neg γδ
T cell expansions and weak CMV-specific CD8+/CD4+ T cell
responses, some had strong CMV-specific CD8+/CD4+ T cell
responses and low frequency of Vδ2neg cells, and some had
high levels of all subsets.
Stability of γδ T cell subsets over time
Herpesvirus-specific T cells are reported to fluctuate over
time [29], so we were interested to learn if Vδ2neg γδ T cells
displayed this behaviour by performing longitudinal analy-
sis on a random selection of six CMV-seropositive and six
CMV-seronegative donors and two cases of primary CMV-
infectious mononucleosis (IM) infection. Vδ2neg cell
numbers varied modestly in healthy donors over time (see
Table 1. Summarized γδ T cell profiles of study subjects.
Age group T cell subset CMV-positive CMV-negative P-value (Mann–Whitney U-test)
21–40 years (n = 39) (n = 58)
Vδ2-negative 2·04% ± 0·3 (29·71 ± 5·75) 1·21% ± 0·08 (14·58 ± 1·5) 0·036 (0·009)
Vδ2-positive 2·62% ± 0·37 (35·5 ± 6·4) 3·37% ± 0·38 (39·5 ± 4·7) 0·134 (0·385)
41–60 years (n = 43) (n = 40)
Vδ2-negative 2·44% ± 0·46 (40·14 ± 9·87) 0·85% ± 0·1 (11·42 ± 1·32) < 0·0001 (0·0003)
Vδ2-positive 2·17% ± 0·44 (29·62 ± 5·9) 2·44% ± 0·32 (34·8 ± 5·1) 0·085 (0·09)
61+ years (n = 43) (n = 32)
Vδ2-negative 3·67% ± 1·03 (58·16 ± 25·66) 0·7% ± 0·09 (7·01 ± 1·09) 0·0004 (< 0·0001)
Vδ2-positive 2·06% ± 0·5 (44·1 ± 13·8) 3·07% ± 0·64 (43·7 ± 8·9) 0·09 (0·472)
Values in the CMV-positive and CMV-negative columns denote means and standard error for each subset as a percentage of total T cells and, in
brackets, absolute numbers per μl of blood. CMV = cytomegalovirus.
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Fig. 4a), mean 29·2% variation in CMV-seropositive and
mean 35·7% in CMV-seronegative donors, while CMV-IM
patients showed a more dramatic reduction in absolute
number of Vδ2neg γδ T cells in samples collected between
1 week post-diagnosis and subsequent time-points
(Fig. 4b). All healthy donors showed very stable phenotypes
at each time-point, but in CMV-IM Vδ2neg γδ T cells were
composed initially of both Tem and TemRA cells, and both
CD27highCD28low and CD27lowCD28low cells during the early
phase of infection. However, after 2 years Vδ2neg γδ T cells
had shifted almost exclusively to the TemRA phenotype, with
a concomitant shift to highly differentiated CD27lowCD28low
cells (Fig. 4c). This change was more dramatic than
those observed in healthy donors. In contrast, Vδ2pos γδ
T cells were composed mainly of less differentiated
CD27highCD28high CD45RAneg central memory T cells (Tcm),
both during acute infection and 3 years later (data not
shown).
Effector memory phenotype and function of
Vδ2neg γδ T cells
The above-described similarity in phenotype between
Vδ2neg γδ T cells and CMV-specific CD8 T cells prompted
further comparative studies. Work by ourselves and others
[5,6,30] has shown that CMV drives CD4+ and CD8+ T cells
towards a highly differentiated Tem and TemRA phenotype.
Because Vδ2neg γδ T cells were increased in CMV carriers
and, in common with CMV-specific CD4+ and CD8+ T cells,
also appeared to increase with age, we hypothesized that
these γδ T cells would also be driven towards a highly differ-
entiated Tem/TemRA phenotype. Figure 5 shows representa-
tive phenotypes of different T cell subsets in representative
CMV-seropositive and CMV-seronegative donors. Vδ2neg γδ
T cells display remarkable similarity to CMV-specific CD8+
T cells in particular and CMV-specific CD4+ T cells to a
lesser degree, but not to Vδ2pos γδ T cells. Vδ2neg γδ T cells in
CMV-seropositive donors were composed of greater
numbers of late memory CD27lowCD28low cells and con-
tained higher levels of intracellular perforin and granzyme
B than in CMV-seronegative donors, indicating greater dif-
ferentiation and functionality of Vδ2neg cells in terms of
cytotoxicity. In contrast, Vδ2neg γδ T cells in CMV-
seronegative donors and Vδ2pos γδ T cells in both sets of
donors were composed mainly of less differentiated Tcm and
Tem cells (Fig. 5a,b). This indicates that CMV carriage leads
to a profound change in phenotype of Vδ2neg γδ T cells, but
not Vδ2pos cells.
We tested freshly isolated Vδ2neg γδ T cells, assumed to
contain effector memory cells that were reactive against
CMV-infected fibroblasts, for their ability to function in ex
vivo. Figure 5c shows that fresh Vδ2neg γδ T cells do not
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Fig. 2. Effect of cytomegalovirus (CMV)
carriage on naive and memory cell composition
of γδ T cell subsets. Peripheral blood
mononuclear cells (PBMC) were stained with T
cell receptor (TCR)-γδ, Vδ2, lymphocyte
function-associated antigen 1 (LFA-1) and
CD45RA monoclonal antibody (mAb). Flow
cytometry plots show LFA-1 (x-axes) versus
CD45RA (y-axes) staining of Vδ2pos and Vδ2neg
γδ T cell subsets in two CMV-seropositive
donors (a) and two CMV-seronegative donors
(b). Staining is shown on a logarithmic scale
from 100 to 104 arbitrary units. LFA-1 versus
CD45RA staining is also shown for CMV
epitope-specific CD8+ T cells for one of the two
CMV-seropositive donors by gating on human
leucocyte antigen (HLA)-A1 (VTE) tetramer
binding CD8+ T cells. Values indicate percentage
of gated cells in each quadrant. Absolute
numbers of naive Vδ2neg γδ T cells were also
compared between age groups (c) and between
CMV-seropositive and CMV-seronegative
(marked as + and – on x-axis, respectively)
donors (d).
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donors. Values on each axis denote the percentage of each cell type as
a percentage of the total T cell repertoire. Significance (P) values at
95% confidence intervals are shown for each set of data. Correlations
were determined using the non-parametric Spearman’s rank test.
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Fig. 4. Dynamics of Vδ2neg γδ T cells in healthy donors over time.
Vδ2pos and Vδ2neg γδ T cell numbers were measured in a longitudinal
analysis of six cytomegalovirus (CMV)-seropositive (top charts) and
six CMV-seronegative healthy donors (bottom charts) (a; both groups
composed of three young and three middle-aged subjects), and also in
two immunocompetent subjects diagnosed with primary CMV
infection (b; aged 38 and 43 years). Phenotypic changes in late
memory and T-effector memory CD45RA-positive (TemRA) cells were
also determined after a 12-month interval in six healthy donors
(CMV-pos; black triangles, CMV-neg; white triangles) and one of the
primary CMV patients (grey circle) (c). T1 represents 1 week
post-diagnosis and T2 denotes 2 years post-diagnosis for the primary
CMV samples. Values shown indicate the percentage of Vδ2neg γδ
T-cells expressing the given phenotype.
Late memory cells
CD27lowCD28low
TemRA cells
CD45RAhiLFA1hi
C
el
ls
/μ
l o
f b
lo
od
100
(a)
(b)
(c)
80
60
40
20
0
0 50 100
Vδ2pos γδ T cells
100
80
60
40
20
0
0 50 100
Vδ2neg γδ T cells
C
el
ls
/μ
l o
f b
lo
od
100
80
60
40
20
0
0 50 100
Weeks
100
80
60
40
20
0
0 50 100
100
80
60
40
20
0
T1 T2
100
80
60
40
20
0
T1 T2
Weeks
C
el
ls
/μ
l o
f b
lo
od
100
80
60
40
20
0
0
Weeks
100
80
60
40
20
0
0 2010 15030
Weeks
2010 15030
%
 o
f V
δ2
ne
g  
ce
lls
CMV distorts γδ T cells over time
423© 2014 British Society for Immunology, Clinical and Experimental Immunology, 176: 418–428
(a) (b)
(c)
4·7 89·3
3·9
5·8
9·9
2·75 11·3
10·7
5·8 5·7
0
35·8 78·2
10·1
6·7 61·4
23·5
0·9
8·0 37·7
20·3
73·1
9·7
2·9 91·6
0·5
3·9 29·7
0·3
48·4 20
5·9
8·5 8·5
1·8
3·6
CMV-pos donor
C
D
28
CD27
Perforin
G
ra
nz
ym
e 
B
0·07
0·04 3·3
0·13 0·18
IFN-gamma
T
 c
el
l
su
bs
et
0·19
0·16
0·14
2·8
CD8
γδ
CD4
CMV-specific
CD8 T cells
CMV-specific
CD4 T cells
MOCK + CMV
+ CMV
+TCR-αβ block
Enriched γδ T cells
+ CMV
0·18
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
Vδ2pos
γδ T cells
Vδ2neg
γδ T cells
Vδ2neg
γδ T cells
Vδ2pos
γδ T cells
CMV-neg donor
Fig. 5. Vδ2neg γδ T-cells share effector memory phenotype, but not ex-vivo effector function, with cytomegalovirus (CMV)-specific αβ T cells. Flow
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produce IFN-γ after co-incubation with CMV-infected
targets. This was also the case when TNF-α production and
CD107 degranulation was measured (data not shown), sug-
gesting that Vδ2neg γδ T cells do not possess immediate
effector function to the same degree as CMV-specific αβ T
cells in our assay system. It was possible that the extremely
efficient recognition of infected targets by virus-specific
CD4+ and CD8+ T cells masked the true potential of the γδ
T cell response. However, this did not appear to be the case,
as antibody blocking, or depletion, of CD4+ and CD8+ T
cells had no enhancing effect on the γδ T cells in our ex-vivo
assay.
To confirm that Vδ2neg γδ T cells had CMV-specific reac-
tivity, we generated γδ T cell lines in vitro from CMV-
seropositive and CMV-seronegative donors. Results show
that T cell lines from both sets of donors, although at higher
levels in CMV-seropositive cases, could produce cytokines
(IFN-γ and TNF-α) and degranulate after co-incubation
with CMV-infected fibroblasts, but not against mock-
infected fibroblasts (Fig. 6a). This recognition could be
blocked, either partially or completely, using the anti-Vδ1
monoclonal antibody but not with the anti-Vδ2 monoclo-
nal antibody (Fig. 6b). This confirmed that Vδ2neg γδ T
cells in our donors were indeed reactive against CMV,
with Vδ1pos γδ T cells being a major component of this
recognition.
Discussion
CMV carriage in healthy humans is generally viewed as
clinically benign, but it is clear that this relationship
involves major perturbations in lymphocyte subsets over
time [2,31,32]. This study is a detailed account of how γδ T
cell subsets are skewed by the combined effects of CMV car-
riage and ageing in healthy individuals. In many older indi-
viduals we observed increased frequencies of Vδ2neg γδ T
cells, which were overwhelmingly of effector memory phe-
notype, a finding that mirrors the inflation of CMV-specific
CD8+ effector T cells in elderly CMV carriers. The clinical
relevance of this broad immune modulation by CMV is
unclear, but is the subject of intense investigation.
While the increase in Vδ2neg cells with ageing in CMV-
seropositive donors was not statistically significant there
was a significant decline in the Vδ2neg cell frequency in
CMV-seronegative donors, suggesting an intimate relation-
ship between CMV carriage and the expansion and long-
term maintenance of this presumed non-adaptive T cell
subpopulation, as also shown by others while this paper was
being prepared [33,34].
Vδ2neg γδ T cell expansions, which were overwhelmingly
Vδ1pos, exceeded 10% of total T cells in several middle-aged
and elderly CMV-seropositive donors. As Vδ2neg γδ T cells
also display reactivity for tumour cells [25], immune
responses against malignant cells in vivo may contribute
towards these T cell expansions. However, the absence of
such expansions in CMV-seronegative donors suggests that
anti-tumour activity has a limited role.
CMV carriage was associated with reduced naive Vδ2neg
cell numbers in each age group, reaching significance in the
elderly. However, naive Vδ2neg γδ T cells were reduced more
significantly in the elderly group as a whole, irrespective of
CMV status. This finding may have also importance, as
attrition in naive CD8+ T cells is linked with reduced immu-
nity in old age [35].
While there was no pattern of correlation between fre-
quencies of Vδ2neg γδ T cells and virus-specific CD4+/CD8+
T cells, there was phenotypic similarity between these
subsets, which are not shared by Vδ2pos γδ T cells. In par-
ticular, Vδ2neg γδ T cells were akin to CMV-specific CD8+ T
IFN-γ
IFN-α
CD107a/b
Mock + CMV
CMV-pos donors 
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
100
100
104
104
103
103
102
102
101
101
0 50 100
IFN-γ pg/ml
150 200
100
100
CMV + IgG
CMV + Vδ2 block
CMV + Vδ1 block
CMV-neg donors
0 50 100
IFN-γ pg/ml
150 200
Mock
(a)
(b)
Fig. 6. Recognition of virus-infected target cells by Vδ2neg γδ T cells.
In-vitro expanded γδ T cell lines tested for the ability to recognize
cytomegalovirus (CMV)-infected (AD169 strain) human fibroblasts.
Representative flow cytometry plots showing cytokine secretion and
degranulation against CMV-infected targets from a CMV-seropositive
donor (a). γδ T cell lines were also tested by interferon (IFN)-γ
enzyme-linked immunosorbent assay (ELISA) after overnight
incubation with CMV-infected stimulators (b). Data are pooled from
independent experiments with T cell lines generated from three
different CMV-seropositive and CMV-seronegative donors.
Mock-infected targets were used as controls with anti-Vδ1, anti-Vδ2
and mouse immunoglobulin (Ig)G antibodies used to block
recognition.
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cells; both are almost exclusively effector cells, including
both Tem and TemRA cells, with a highly differentiated
CD27lowCD28low phenotype. Vδ2neg γδ T cells also expressed
high levels of markers of cytotoxicity (perforin and
granzyme B), similar to both CMV-specific CD8+ and CD4+
T cells. In contrast, Vδ2pos γδ T cells were mainly CD45RAlow
(CD45ROhigh), CD27highCD28high and heterogeneous for
cytotoxicity markers.
Highly differentiated Vδ2neg γδ T cells in healthy people
were very stable in number and phenotype over 3 years.
However, the picture was more dynamic after primary
infection. In the acute phase, the response was composed
mainly of Tem (CD45RAlow) and TemRA (CD45RAhigh) cells,
but this response had rapidly contracted and shifted to an
overwhelmingly TemRA phenotype with a concomitant shift
towards end-stage highly differentiated cells. Conversely, no
significant change in Vδ2pos γδ T cell phenotype was
observed. This analysis involved limited patient numbers,
but the findings are consistent with those described in
immunosuppressed CMV-infected transplant patients and
CMV-infected newborns [23,24,26,33].
We confirmed Vδ2neg γδ T cell reactivity against CMV-
infected cells using in-vitro-expanded T cell lines. However,
we could not demonstrate immediate effector activity using
freshly isolated Vδ2neg cells in ex-vivo assays, which was
unexpected given the shared effector memory phenotype of
Vδ2neg γδ T cells and virus-specific αβ T cells. Being a dis-
tinct T cell lineage, γδ T cells may require an additional acti-
vation signal, but the observed result could also be a
reflection of our experimental conditions; CMV-infected
fibroblasts, while able to sensitize virus-specific CD4+ and
CD8+ T cells, may not have expressed sufficient levels of the
ligand(s) for optimal stimulation of freshly isolated Vδ2neg
γδ T cells. The use of non-autologous fibroblasts could also
be problematic if stimulation occurs via an autologous non-
MHC pathway. Another possibility is that Vδ2neg γδ T cells
are driven to exhaustion, as described for CMV-specific αβ
T cells in elderly people [9,36,37] and CD8+ T cells with the
CD28low/CD57high phenotype [38,39]. Further work is neces-
sary to test senescence in Vδ2neg γδ T cells, although some
caution is warranted when assessing function, as our
experiments are based solely on circulating γδ T cells in the
blood, and not from mucosal sites where Vδ2neg γδ T cells
are likely to be functionally more active. Of particular note,
CMV-reactivity was also displayed using Vδ2neg cell lines
derived from CMV-seronegative donors. This state of readi-
ness for expansion in CMV-seronegative donors provides
support for these cells having a central role in the immune
response after primary infection, and also highlights their
potential in cellular immunotherapy of viral disease in
CMV-seronegative patients.
Unlike for other T cell subsets, data on ligands for Vδ2neg
γδ T cells have been lacking, but this field is rapidly evolv-
ing. Willcox and colleagues have recently identified a stress
ligand called endothelial protein C receptor, which is recog-
nized by γδ TCR belonging to a Vδ5 T cell clone with dual
CMV-specific and epithelial tumour-specific reactivity [40].
Furthermore, it has been shown that Vδ2neg γδ T cells can be
activated via CD16 engagement in a TCR-independent
manner [41]. This may involve ligation via CMV-specific
antibodies, as a positive correlation between anti-CMV IgG
titres and Tem Vδ2neg γδ T cells has been reported [34]. The
discovery of additional ligands and activation pathways,
especially for other more numerically dominant Vδ2neg cells
(namely Vδ1pos), is keenly awaited. It will be of interest to
learn whether these ligands play a role in direct recognition
of CMV-infected cells, indirect recognition of antigens
cross-presented by professional antigen-presenting cells
[42], recognition during latency [43] and after reactivation
from latency. Ligand information will also be of immense
value for CMV vaccine research [44], where the aim is to
elicit broad multi-specific immunity [45]. Furthermore, it
will be crucial to learn if Vδ2neg γδ T cells are subject to
immune-evasion by CMV, which is the case for other T cells
and for natural killer (NK) cells [46].
To summarize, Vδ2neg γδ T cells are increased in CMV
carriers and particularly in more aged subjects. Given the
reported shared reactivity of Vδ2neg γδ T cells for CMV and
epithelial tumour cells [25] and the greater incidence of
cancer in the elderly, this finding may have great signifi-
cance. Indeed, CMV seropositivity and increased numbers
of Vδ2neg γδ T cells coincide with lower risk of cancer in
kidney transplant patients [47]. Further independent
studies of CMV status and Vδ2neg γδ T cells in cancer
patients are thus a major priority for the future.
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Fig. S1. Flow cytometry plots showing peripheral blood
mononuclear cells (PBMC) stained with pan-T cell receptor
(TCR)-γδ and anti-Vδ1 or anti-Vδ2 monoclonal antibodies
from two cytomegalovirus (CMV)-seronegative (a) and two
CMV-seropositive healthy donors (b). Values shown in the
two upper quadrants of each plot indicate the percentage of
lymphocytes staining for each γδ subset.
Fig. S2. Analysis of memory Vδ2neg γδ T-cells in cytomeg-
alovirus (CMV)-seropositive (a) and CMV-seronegative
donors (b) of different age groups. Charts show the abso-
lute numbers of memory Vδ2neg γδ T cells in subjects as
determined by co-staining with CD45RA and lymphocyte
function-associated antigen 1 (LFA-1). Memory cells com-
prised both T effector memory (Tem) and T effector
memory CD45RA-positive (TemRA) cells (see Fig. 2).
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